Physiomics to present at AACR Annual Meeting
Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it is participating in the American Association for Cancer Research Annual Meeting 2023, being held on 14-19 April 2023 in Orlando, FL.
The Company will give an oral presentation entitled “Development and validation of a quantitative systems pharmacology model for prediction of preclinical efficacy of PARP inhibitors rucaparib and talazoparib combined with the ATR inhibitor gartisertib (M4344)”. Physiomics is co-authoring the presentation with client Merck KGaA.
This newly developed quantitative systems pharmacology model, part of our Virtual Tumour platform, provides a framework that can be applied to optimise the dosing regimens of PARP and ATR inhibitor combinations and help with clinical dosing strategy.
The presentation will be given by Dr Nathalie Dupuy, Senior Biosimulation Scientist, on 18 April 16:07-16:22 EDT (21:07-21:22 BST). The abstract (#5699) is available at the conference website via this link. A copy of the presentation will be posted on Physiomics’ website at 17:00 EDT (22:00 BST) on the same day at: www.physiomics.co.uk/resources.
More information about the conference may be found at:
Executive Chairman & CEO, Dr Jim Millen, said: “Being awarded a talk at a high-profile conference such as AACR is a testimony to the scientific quality of our team. We are excited to present publicly for the first time on our collaborative work with Merck, and we are looking forward to meeting with other attendees of the conference.”
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company’s Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics’ technologies have been confirmed by over 100 projects, involving over 50 targets and 75 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.